ClinicalTrials.gg
TerminatedNCT02158936Updated Dec 12, 2017Results posted

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

A Phase 3 interventional study of Eltrombopag and Azacitidine in Thrombocytopaenia, sponsored by Novartis Pharmaceuticals. Terminated at 158 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-12.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
356
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies testing eltrombopag in Thrombocytopenia — 2 open to participants now, 3 under way, none of them phase 3. eltrombopag · Thrombocytopenia.

Enrollment
Largest of 53
356 · median 40
Started
2014
with 3 others
Phase 3
9 of 53
none open now
Registered
43rd of 53
by date
Lead sponsor
6 of 53
Novartis Pharmaceuticals

Among the 53 studies testing eltrombopag in Thrombocytopenia, this one has the largest enrollment, is one of 4 that started in 2014, is one of 9 in phase 3, and was the 43rd registered.

Thrombocytopenia

484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.

Browse Thrombocytopenia studies →

Open to participants now

2 of the 53 studies testing eltrombopag in Thrombocytopenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies testing eltrombopag in Thrombocytopenia, or all of them as a file.
02

Study summary

Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with thrombocytopenia. Eltrombopag has been shown to increase platelet counts in patients with thrombocytopenia from various etiologies (Idiopathic thrombocytopenic purpura [ITP], liver disease, aplastic anemia and chemotherapy induced thrombocytopenia). Approximately 350 subjects will be randomized in a 1:1 ratio (175 into the eltrombopag arm and 175 into the placebo arm). Approximately 55 subjects will be enrolled into the azacitidine. Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of \<75 Giga (10\^9) per liter (Gi/L) will only be enrolled. This is a randomized, double-blind, parallel group, placebo-controlled study designed to explore the platelet supportive care effects of eltrombopag versus placebo in combination with the standard of care hypomethylating agent, azacitidine. The primary objective of this study is to determine the effect of eltrombopag versus placebo on the proportion of subjects who are platelet transfusion free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease progression.

03

Conditions studied

  • Thrombocytopaenia

Keywords

  • thrombocytopenia
  • myelodysplastic syndromes
  • MDS
  • thrombopoietin
  • azacitidine
  • Eltrombopag
  • myelodysplastic syndromes (MDS)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >=18 years (For subjects in Taiwan, Age >= 20 years)
  • MDS by World Health Organization (WHO) or French-American-British (FAB) classification
  • Intermediate 1, intermediate 2 or high risk MDS by IPSS
  • At least one count \< 75 Gi/L
  • (ECOG) Status 0-2
  • Adequate baseline organ function defined by the criteria below: total =\< 1.5x the (ULN) except for Gilbert's syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect [haemolytic] bilirubin in the absence of [ALT] abnormality); ALT =\< 2.5xULN; creatinine =\< 2.5xULN
  • Subjects with a interval (QTc) \<450 milliseconds (msec) or \<480msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine or manual overread. For subject eligibility and withdrawal, QTcF will be used. For purposes of data analysis, QTcF will be used. The QTc should be based on single or averaged QTc values of triplicate (ECGs) obtained over a brief recording period
  • Subject is able to understand and comply with protocol requirements and instructions
  • Subject has signed and dated
  • Women must be either of non-child bearing potential, or women with and men with must be willing to practice acceptable methods of during the study
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 3 months following the last dose of study treatment
  • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of randomization until 16 weeks after the last dose of study treatment
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with hypomethylating agent or induction chemotherapy for MDS
  • Proliferative type chronic myelomonocytic leukemia with white blood cell count >12 Gi/L at any time during the 28 days before Day 1
  • History of treatment with eltrombopag, romiplostim or other thrombopoietin receptor (TPO-R) agonists
  • Previous stem-cell transplantation
  • Known thrombophilic risk factors. Exception: Subjects for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator
  • Treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo)
  • Active and uncontrolled infections, including or C
  • (HIV) infection
  • Known immediate or delayed reaction or idiosyncrasy to drugs chemically related to eltrombopag or its , or azacitidine, that contraindicates the subjects' participation
  • Pregnant or lactating female
  • Any serious and/or unstable pre-existing medical condition (including any advanced other than the disease under study), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining or compliance with the study procedures
  • French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
356 participants (actual)

Study arms

  • Experimental
    Eltrombopag

    Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine

    Drug: Eltrombopag · Drug: Azacitidine

  • Placebo comparator
    Placebo

    Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter\^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine

    Drug: Azacitidine · Drug: Placebo

Interventions

  • Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid

  • Subcutaneous Injection (IV if local standard)

  • DrugPlacebo

    Eltrombopag matching placebo tablets

  • DrugPlacebo

    Eltrombopag matching placebo tablets will be supplied

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy

    A subject is defined as being platelet transfusion independent if they received no platelet transfusions within the first 4 cycles of treatment with azacitidine. Subjects who died or withdrew from investigational product within the first four cycles were treated as failures (i.e. not transfusion independent) in the analysis

    Time frame: 4 cycles (Cycle = 28 days)

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization until death due to any cause and deaths have been presented. Subjects still alive at the time of the analysis and subjects who have withdrawn from the study will be censored at the time of last contact

    Time frame: Randomization until death or end of study, approximately 2 years

  2. Summary of Progression Free Survival From Investigator Assessment (ITT)

    Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts

    Time frame: First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years

  3. Summary of Progression Free Survival From Central Review (ITT)

    Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts

    Time frame: First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years

  4. Summary of AML Progression From Investigator Assessment and Central Review (ITT)

    Progression to AML in MDS patients with baseline bone marrow blast \< 20% was defined as meeting definition of disease progression according to the modified 2006 IWG response criteria for MDS with the additional requirement that bone marrow blast or peripheral blast increases from \< 20% at baseline to ≥ 20% postbaseline. Progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts

    Time frame: First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years

  5. Best Disease Response From Investigator Assessment (ITT)

    Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS

    Time frame: At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first

  6. Best Disease Response From Central Review (ITT)

    Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS

    Time frame: At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first

  7. Hematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)

    HI based on the modified IWG criteria for MDS. HI - Platelets (BL \<100Gi/L), response criteria= BL \<20: increase to\>20 and 100% at least for 56 days or BL \>=20: absolute increase of \>=30. HI - Neutrophils (BL \<1.0 Gi/L), response criteria=100% increase and an absolute increase \>0.5 Gi/L over BL for at least 56 days. HI-Hemoglobin (BL \<g/dL), response criteria=Hgb increase by \>=1.5 g/dL over BL, RBC transfusions(given for Hgb\<=9.0) reduced by \>=4 per 8w from BL

    Time frame: From Day 1 to 4-week follow-up (samples collected weekly in Cycle 1, Days 1 and 15 in Cycles 2-6 and Day 1 of Cycles >=7)

  8. Number of Participants Who Were Platelet Transfusion Independent (ITT Set)

    Platelet transfusion independence is defined for each cycle as the number of participants who continue to the end of a cycle without requiring a platelet transfusion

    Time frame: From Day 1 to end of study treatment up to approximately 2 years

  9. Bleeding Adverse Events (AEs) >= Grade 3

    Bleeding will be assessed by recording AEs or serious adverse events (SAEs) as graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0

    Time frame: From Day 1 to 4-week follow-up up to approximately 2 years

  10. Number of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions

    The proportion of subjects with any delay, reduction or interruption in dosage of Azacitidine excluding those for non-medical reasons will be analyzed

    Time frame: From Day 1 to 4-week follow-up up to approximately 2 years

  11. Response Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)

    The EQ-5D is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (EQ-5D is a trademark of the Stichting EuroQol Group) . C=cycle, D=Day

    Time frame: From Day 1 to 4-week follow-up up to approximately 2 years

  12. Functional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)

    The FACIT-Fatigue subscale measures severity and impact of fatigue on functioning and Health Related QoL experienced in the past 7 days. Scale is a 13 item measure of fatigure. Items are scored on a 0-4 response scale ranging from "not at all" to "very much so". All items are summed to create a single fatigure score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatiigue (The FACIT Fatigue Scale is owned by David Cella, Ph.D.)

    Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years

  13. Medical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient

    MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations

    Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years

  14. Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests

    MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected

    Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years

  15. Medical Resource Utilization (MRU): Use of Site Specific Medical Resources

    MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected

    Time frame: From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years

  16. Summary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose

    Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)

    Time frame: Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose

  17. Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose

    Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)

    Time frame: Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose

  18. AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine

    An analysis of variance (ANOVA) on AUC0-infinity. The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + eltrombopag:azacitidine + placebo PK parameter ratios.

    Time frame: Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose

  19. Cmax -Pharmacokinetic Parameter of Azacitidine

    An analysis of variance (ANOVA) on Cmax . The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + ltrombopag:azacitidine + placebo PK parameter ratios.

    Time frame: Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose

07

Results

Posted Dec 12, 2017
Limitations and caveats
The IDMC recommended terminating the study for futility (primary) and safety (secondary). Due to early termination of the trial, the final analysis of OS took place at the same time as the final analysis of the primary end point.

Participant flow

Participant flow — Overall Study
MilestoneEltrombopagPlacebo
Started179177
Treated177177
Untreated20
Completed00
Not completed179177
Withdrew: Study closed/ terminated5777
Withdrew: Azacitidine tx discontinued5346
Withdrew: Adverse event3924
Withdrew: Withdrawal by subject1516
Withdrew: Physician decision1513
Withdrew: Lost to follow-up01

Outcome measures

PrimaryNumber of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy

A subject is defined as being platelet transfusion independent if they received no platelet transfusions within the first 4 cycles of treatment with azacitidine. Subjects who died or withdrew from investigational product within the first four cycles were treated as failures (i.e. not transfusion independent) in the analysis

Time frame:
4 cycles (Cycle = 28 days)
Reported as:
Number · Participants
Number of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy
ParticipantsEltrombopagPlacebo
Yes - platelet transfusion independent2855
No - platelet transfusion independent151122
Statistical analysis
  • Eltrombopag vs Placebo · Cochran-Mantel-Haenszel · p = 1.000 (One sided p value) · Odds ratio (or): 0.37 · 95% CI 0.21 to 0.65Stratified by Interactive Voice Response System (IVRS) stratification factors
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization until death due to any cause and deaths have been presented. Subjects still alive at the time of the analysis and subjects who have withdrawn from the study will be censored at the time of last contact

Time frame:
Randomization until death or end of study, approximately 2 years
Reported as:
Number · deaths (events)
Overall Survival (OS)
deaths (events)EltrombopagPlacebo
Overall Survival (OS)5751
Statistical analysis
  • Eltrombopag vs Placebo · Log Rank · p = 0.164 · Hazard ratio (hr): 1.42 · 95% CI 0.97 to 2.08
SecondarySummary of Progression Free Survival From Investigator Assessment (ITT)

Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts

Time frame:
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Reported as:
Number · participants
Summary of Progression Free Survival From Investigator Assessment (ITT)
participantsEltrombopagPlacebo
Death3436
Disease progression3830
SecondarySummary of Progression Free Survival From Central Review (ITT)

Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts

Time frame:
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Reported as:
Number · participants
Summary of Progression Free Survival From Central Review (ITT)
participantsEltrombopagPlacebo
Death4441
Disease progression3226
SecondarySummary of AML Progression From Investigator Assessment and Central Review (ITT)

Progression to AML in MDS patients with baseline bone marrow blast \< 20% was defined as meeting definition of disease progression according to the modified 2006 IWG response criteria for MDS with the additional requirement that bone marrow blast or peripheral blast increases from \< 20% at baseline to ≥ 20% postbaseline. Progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to \> 5% blasts; 5% - \<10% BM blasts: ≥ 50% increase to \> 10% blasts; 10% - \<20% BM blasts: ≥ 50% increase to \> 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to \> 30% blasts

Time frame:
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Reported as:
Number · participants
Summary of AML Progression From Investigator Assessment and Central Review (ITT)
participantsEltrombopagPlacebo
Participants progressed-AML - investigator assess2716
Participants progressed to AML - Central Review2110
SecondaryBest Disease Response From Investigator Assessment (ITT)

Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS

Time frame:
At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Reported as:
Number · participant
Best Disease Response From Investigator Assessment (ITT)
participantEltrombopagPlacebo
Complete response - CR1526
Marrow complete response814
Partial response - PR1322
Stable disease5047
Progressive disease228
Not evaluable3233
Overall Response (CR+Marrow+PR3662
SecondaryBest Disease Response From Central Review (ITT)

Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS

Time frame:
At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Reported as:
Number · participant
Best Disease Response From Central Review (ITT)
participantEltrombopagPlacebo
Complete response - CR117
Marrow complete response25
Partial response - PR27
Stable disease2331
Progressive disease2417
Not evaluable2638
Overall Response (CR+Marrow+PR)1519
SecondaryHematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)

HI based on the modified IWG criteria for MDS. HI - Platelets (BL \<100Gi/L), response criteria= BL \<20: increase to\>20 and 100% at least for 56 days or BL \>=20: absolute increase of \>=30. HI - Neutrophils (BL \<1.0 Gi/L), response criteria=100% increase and an absolute increase \>0.5 Gi/L over BL for at least 56 days. HI-Hemoglobin (BL \<g/dL), response criteria=Hgb increase by \>=1.5 g/dL over BL, RBC transfusions(given for Hgb\<=9.0) reduced by \>=4 per 8w from BL

Time frame:
From Day 1 to 4-week follow-up (samples collected weekly in Cycle 1, Days 1 and 15 in Cycles 2-6 and Day 1 of Cycles >=7)
Reported as:
Number · participants
Hematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)
participantsEltrombopagPlacebo
Platelets5657
Neutrophils1213
Hemoglobin11
Platelets and neutrophils1011
Platelets and hemoglobin11
Neutrophils and hemoglobin11
Platelets, neutrophils and hemoglobin11
SecondaryNumber of Participants Who Were Platelet Transfusion Independent (ITT Set)

Platelet transfusion independence is defined for each cycle as the number of participants who continue to the end of a cycle without requiring a platelet transfusion

Time frame:
From Day 1 to end of study treatment up to approximately 2 years
Reported as:
Number · participants
Number of Participants Who Were Platelet Transfusion Independent (ITT Set)
participantsEltrombopagPlacebo
Screening (179,177)127121
Cycle 1 (175,173)6887
Cycle 2 (135,158)6287
Cycle 3 (105,131)6894
Cycle 4 (93,116)5891
Cycle 5 (76,108)4976
Cycle 6 (65,90)4162
Cycle 7 (47,74)2950
Cycle 8 (37,61)2042
Cycle 9 (28,46)1936
Cycle 10 (23,38)1828
Cycle 11 (19,29)1320
Cycle 12 (15,21)1015
Cycle 13 (12,16)710
Cycle 14 (6,11)36
Cycle 15 (3,5)23
Cycle 16 (0,3)03
Cycle 17 (0,3)00
SecondaryBleeding Adverse Events (AEs) >= Grade 3

Bleeding will be assessed by recording AEs or serious adverse events (SAEs) as graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0

Time frame:
From Day 1 to 4-week follow-up up to approximately 2 years
Reported as:
Number · participant
Bleeding Adverse Events (AEs) >= Grade 3
participantEltrombopagPlacebo
Any event - Grade 3912
Any event - Grade 422
Any event - Grade 514
SecondaryNumber of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions

The proportion of subjects with any delay, reduction or interruption in dosage of Azacitidine excluding those for non-medical reasons will be analyzed

Time frame:
From Day 1 to 4-week follow-up up to approximately 2 years
Reported as:
Number · participant
Number of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions
participantEltrombopagPlacebo
Overall dose delay8288
Overall dose reduction716
Overall dose interruption313
SecondaryResponse Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)

The EQ-5D is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (EQ-5D is a trademark of the Stichting EuroQol Group) . C=cycle, D=Day

Time frame:
From Day 1 to 4-week follow-up up to approximately 2 years
Reported as:
Number · participant
Response Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)
participantEltrombopagPlacebo
Mobility C1, D1 (176, 173) L1- no problem walking94105
Mobility C1,D1 (176, 173) L2- some problem walking8166
Mobility C1, D1 (176,173) L3- confined to bed12
Mobility Wk 4 FU (71,72) L1- no problem walking4048
Mobility Wk 4 FU (71,72) L2- some problem walking2922
Mobility Wk 4 FU (71,72) L3- confined to bed22
Self-Care C1, D1 (176,173) L1-no problems140125
Self-Care C1, D1 (176,173) L2-some problems3220
Self-Care C1, D1 (176,173) L3-unable to451
Self-Care Wk4 FU (71,72) L1-no problems5662
Self-Care Wk4 FU(71,72) L2-some problems139
Self-Care Wk4 FU (71,72) L2-unable to wash/dress21
Usual activities C1,D1(175,173) L1-no problem9794
Usual activities C1,D1(175,173) L2-some problem7168
Usual activities C1,D1(175,173) L3-unable to711
Usual activities Wk4 FU (71,72) L1-no problem3641
Usual activities Wk4 FU (71,72) L1-some problem2925
Usual activities Wk4 FU (71,72) L3-unable to66
Pain/discomfort C1,D1(176,173) L1-none9789
Pain/discomfort C1,D1(176,173) L2-moderate7478
Pain/discomfort C1,D1(176,173) L3-extreme56
Pain/discomfort Wk4 FU (71,72) L1-none3840
Pain/discomfort Wk4 FU (71,72) L2-moderate2827
Pain/discomfort Wk4 FU (71,72) L3-extreme55
Anxiety/depression C1 D1(176,173) L1-none96112
Anxiety/depression C1 D1(176,173) L2-moderately7456
Anxiety/depression C1 D1(176,173) L3-extremely65
Anxiety/depression Wk4 FU(71,72) L1-none4445
Anxiety/depression Wk4 FU(71,72) L2-moderately2425
Anxiety/depression Wk4 FU(71,72) L3-extremely32
SecondaryFunctional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)

The FACIT-Fatigue subscale measures severity and impact of fatigue on functioning and Health Related QoL experienced in the past 7 days. Scale is a 13 item measure of fatigure. Items are scored on a 0-4 response scale ranging from "not at all" to "very much so". All items are summed to create a single fatigure score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatiigue (The FACIT Fatigue Scale is owned by David Cella, Ph.D.)

Time frame:
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Reported as:
Mean · scores
Functional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)
scoresEltrombopagPlacebo
Cycle 1 Day 1 (175,172)17.401 ± 11.027915.951 ± 10.9911
Week 4 Follow-up (68,70)16.669 ± 10.726614.898 ± 12.2362
SecondaryMedical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient

MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations

Time frame:
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Reported as:
Mean · days
Medical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient
daysEltrombopagPlacebo
In-patient hospitalizations - entire study (91,66)23.9 ± 24.3327.1 ± 33.81
Out-patient hospitalizations - entire study (4,2)9.5 ± 16.342.5 ± 0.71
SecondaryMedical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests

MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected

Time frame:
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Reported as:
Number · tests
Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests
testsEltrombopagPlacebo
Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests88105
SecondaryMedical Resource Utilization (MRU): Use of Site Specific Medical Resources

MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected

Time frame:
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Reported as:
Number · visits
Medical Resource Utilization (MRU): Use of Site Specific Medical Resources
visitsEltrombopagPlacebo
Medical or surgical specialist visits4958
Home healthcare visits by medical professional8997
Primary physician care visits8997
Nurse practitioner, physic assistant, nurse visits8997
Telephone consultations8997
Emergency visits not resulting in hospital stay8997
SecondarySummary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose

Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)

Time frame:
Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Reported as:
Geometric mean · μg/mL
Summary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose
μg/mLEltrombopag
Cmax7.70 ± 36.8
Cmin4.41 ± 49.9
SecondarySummary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose

Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)

Time frame:
Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Reported as:
Geometric mean · hr.μg/mL
Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose
hr.μg/mLEltrombopag
Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose135 ± 43.1
SecondaryAUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine

An analysis of variance (ANOVA) on AUC0-infinity. The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + eltrombopag:azacitidine + placebo PK parameter ratios.

Time frame:
Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
Reported as:
Geometric mean · hr.ng/mL
AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine
hr.ng/mLEltrombopagPlacebo
AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine840 ± 53641 ± 67
Statistical analysis
  • Eltrombopag vs Placebo · ANOVA · Geometric mean ratio: 1.31 · 90% CI 0.990 to 1.74
SecondaryCmax -Pharmacokinetic Parameter of Azacitidine

An analysis of variance (ANOVA) on Cmax . The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + ltrombopag:azacitidine + placebo PK parameter ratios.

Time frame:
Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
Reported as:
Geometric mean · ng/mL
Cmax -Pharmacokinetic Parameter of Azacitidine
ng/mLEltrombopagPlacebo
Cmax -Pharmacokinetic Parameter of Azacitidine744 ± 91535 ± 89
Statistical analysis
  • Eltrombopag vs Placebo · ANOVA · Geometric mean ratio: 1.39 · 90% CI 0.970 to 1.99

Adverse events

Collected over Timeframe for AE. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag—128/177 (72.3%)159/177 (89.8%)
Placebo—100/177 (56.5%)153/177 (86.4%)
Most frequent serious events
Showing 10 of 223
Most frequent serious events
EventEltrombopagPlacebo
Febrile neutropeniaBlood and lymphatic system disorders47/17733/177
PyrexiaGeneral disorders20/1778/177
PneumoniaInfections and infestations20/17717/177
SepsisInfections and infestations10/1777/177
Septic shockInfections and infestations10/1775/177
AnaemiaBlood and lymphatic system disorders5/1777/177
Acute kidney injuryRenal and urinary disorders7/1772/177
CellulitisInfections and infestations6/1772/177
Gastrointestinal haemorrhageGastrointestinal disorders1/1775/177
Urinary tract infectionInfections and infestations4/1775/177
Most frequent other events
Showing 10 of 46
Most frequent other events
EventEltrombopagPlacebo
ConstipationGastrointestinal disorders48/17757/177
NauseaGastrointestinal disorders54/17746/177
NeutropeniaBlood and lymphatic system disorders52/17744/177
PyrexiaGeneral disorders44/17740/177
DiarrhoeaGastrointestinal disorders42/17725/177
AstheniaGeneral disorders28/17734/177
VomitingGastrointestinal disorders33/17729/177
AnaemiaBlood and lymphatic system disorders32/17719/177
FatigueGeneral disorders31/17727/177
CoughRespiratory, thoracic and mediastinal disorders23/17729/177

Baseline characteristics

Age, Continuous
Age, Continuous(years)EltrombopagPlaceboTotal
Mean68.3 ± 12.8269.4 ± 10.5868.8 ± 11.76
Sex: Female, Male
Sex: Female, Male(Participants)EltrombopagPlaceboTotal
Female6953122
Male110124234
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EltrombopagPlaceboTotal
White146148294
East Asian/Japanese/S.E. Asian262349
Central/South Asian022
Other448
Missing303
IPSS risk score
IPSS risk score(participants)EltrombopagPlaceboTotal
Int - 1 (0.5-1.0)6461125
Int - 2 (1.5 - 2.0)7783160
High Risk (≥ 2.5)383371
Platelet Count
Platelet Count(participants)EltrombopagPlaceboTotal
< 10101020
≥ 10 - <20353065
≥ 20 - <508384167
≥ 50 - <1004953102
≥ 100000
missing202
Platelet transfusion dependence
Platelet transfusion dependence(participants)EltrombopagPlaceboTotal
Yes293766
No150140290
08

Study locations

158 sites
  • Novartis Investigative Site
    Hartford, Connecticut 06105, United States
  • Novartis Investigative Site
    Atlanta, Georgia 30322, United States
  • Novartis Investigative Site
    Chicago, Illinois 60612, United States
  • Novartis Investigative Site
    Anderson, Indiana 46016, United States
  • Novartis Investigative Site
    Kansas City, Missouri 64128, United States
  • Novartis Investigative Site
    San Luis, Missouri 63110, United States
  • Novartis Investigative Site
    Bronx, New York 10461, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Novartis Investigative Site
    Seattle, Washington 98108, United States
  • Novartis Investigative Site
    Milwaukee, Wisconsin 53226, United States
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, 1114, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, 1425, Argentina
  • Novartis Investigative Site
    Ciudad Autonoma de Buenos Aires, C1181ACH, Argentina
  • Novartis Investigative Site
    Santa Fe, S3000ADL, Argentina
  • Novartis Investigative Site
    Kogarah, New South Wales 2217, Australia
  • Novartis Investigative Site
    Adelaide, South Australia 5000, Australia
  • Novartis Investigative Site
    Clayton, Victoria 3168, Australia
  • Novartis Investigative Site
    East Melbourne, Victoria 3002, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3000, Australia
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Innsbruck, A-6020, Austria
  • Novartis Investigative Site
    Linz, 4020, Austria
  • Novartis Investigative Site
    Rankweil, A-6830, Austria
  • Novartis Investigative Site
    Salzburg, A-5020, Austria
  • Novartis Investigative Site
    Steyr, 4400, Austria
  • Novartis Investigative Site
    Vienna, 1140, Austria
  • Novartis Investigative Site
    Brasschaat, 2930, Belgium
  • Novartis Investigative Site
    Brugge, 8000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Lodelinsart, 6042, Belgium
  • Novartis Investigative Site
    Turnhout, 2300, Belgium
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Novartis Investigative Site
    Curitiba, Paraná 81520-060, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande Do Sul 90035-903, Brazil
  • Novartis Investigative Site
    Florianopolis, Santa Catarina 88034-000, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 01236030, Brazil
  • Novartis Investigative Site
    Sao Paulo, São Paulo 08270-070, Brazil
  • Novartis Investigative Site
    Rio de Janeiro, 20211-030, Brazil
  • Novartis Investigative Site
    Sao Paulo - SP, 01323-900, Brazil
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
  • Novartis Investigative Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Novartis Investigative Site
    Quebec, G1J 1Z4, Canada
  • Novartis Investigative Site
    Québec, G1J 1Z4, Canada
  • Novartis Investigative Site
    Brno, 625 00, Czechia
  • Novartis Investigative Site
    Ostrava, 708 52, Czechia
  • Novartis Investigative Site
    Praha 10, 100 34, Czechia
  • Novartis Investigative Site
    Praha 2, 128 08, Czechia
  • Novartis Investigative Site
    Praha, 128 20, Czechia
  • Novartis Investigative Site
    Aarhus, 8000 C, Denmark
  • Novartis Investigative Site
    Koebenhavn Oe, 2100, Denmark
  • Novartis Investigative Site
    Angers Cedex 9, 49933, France
  • Novartis Investigative Site
    Caen Cedex 9, 14033, France
  • Novartis Investigative Site
    Le Mans, 72000, France
  • Novartis Investigative Site
    Paris Cedex 12, 75571, France
  • Novartis Investigative Site
    Paris, 75010, France
  • Novartis Investigative Site
    Pringy Cedex, 74374, France
  • Novartis Investigative Site
    Stuttgart, Baden-Wuerttemberg 70199, Germany
  • Novartis Investigative Site
    Muenchen, Bayern 81675, Germany
  • Novartis Investigative Site
    Goettingen, Niedersachsen 37075, Germany
  • Novartis Investigative Site
    Duesseldorf, Nordrhein-Westfalen 40225, Germany
  • Novartis Investigative Site
    Duesseldorf, Nordrhein-Westfalen 40479, Germany
  • Novartis Investigative Site
    Duisburg, Nordrhein-Westfalen 47166, Germany
  • Novartis Investigative Site
    Dresden, Sachsen 01307, Germany
  • Novartis Investigative Site
    Athens,, 11 527, Greece
  • Novartis Investigative Site
    Larisa, 41 110, Greece
  • Novartis Investigative Site
    Patra, 26500, Greece
  • Novartis Investigative Site
    Thessaloniki, 54636, Greece
  • Novartis Investigative Site
    Thessaloniki, 54642, Greece
  • Novartis Investigative Site
    Chai Wan, Hong Kong
  • Novartis Investigative Site
    Hong Kong, Hong Kong
  • Novartis Investigative Site
    Shatin, New Territories, Hong Kong
  • Novartis Investigative Site
    Tuen Mun, Hong Kong
  • Novartis Investigative Site
    Debrecen, 4012, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Dublin, 7, Ireland
  • Novartis Investigative Site
    Galway, Ireland
  • Novartis Investigative Site
    James Street, 8, Ireland
  • Novartis Investigative Site
    Limerick, Ireland
  • Novartis Investigative Site
    Tallaght, Dublin, 24, Ireland
  • Novartis Investigative Site
    Haifa, 31096, Israel
  • Novartis Investigative Site
    Holon, 58100, Israel
  • Novartis Investigative Site
    Jerusalem, 91031, Israel
  • Novartis Investigative Site
    Jerusalem, 91120, Israel
  • Novartis Investigative Site
    Kfar Saba, 44281, Israel
  • Novartis Investigative Site
    Petach-Tikva, 49100, Israel
  • Novartis Investigative Site
    Tel Aviv, 64239, Israel
  • Novartis Investigative Site
    Reggio Calabria, Calabria 89100, Italy
  • Novartis Investigative Site
    Modena, Emilia-Romagna 41124, Italy
  • Novartis Investigative Site
    Genova, Liguria 10126, Italy
  • Novartis Investigative Site
    Novara, Piemonte 28100, Italy
  • Novartis Investigative Site
    Firenze, Toscana 50134, Italy
  • Novartis Investigative Site
    Seoul, 05505, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06351, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 06591, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 135-710, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 137-701, Korea, Republic of
  • Novartis Investigative Site
    Seoul, 138-736, Korea, Republic of
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Oaxaca, 68000, Mexico

Showing the first 100 of 158 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U; SUPPORT study investigators. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia. Blood. 2018 Dec 20;132(25):2629-2638. doi: 10.1182/blood-2018-06-855221. Epub 2018 Oct 10. PubMed 30305280 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2014 to primary completion in Apr 2016, 22 months.

Results were first posted in Dec 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2014
First posted
Jun 9, 2014
StartActual
Jun 10, 2014
Primary completionActual
Apr 30, 2016
CompletionActual
Apr 30, 2016
Results first posted
Dec 12, 2017
Last update
Dec 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02158936
Responsible party
Sponsor
First posted
Jun 9, 2014
Start date
Jun 10, 2014
Primary completion
Apr 30, 2016
Completion
Apr 30, 2016
Results posted
Dec 12, 2017
Last update
Dec 12, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion